454 Says Q3 Revenues Surge 70 Percent; CuraGen Still Mulls Its Stake | GenomeWeb
NEW YORK (GenomeWeb News) — 454 Life Sciences today said third-quarter revenue increased 70 percent to $9.9 million from $5.8 million year over year.
 
The CuraGen subsidiary said 454 made $4.8 million from sales of instruments and reagents and $2.8 million from sequencing service revenue. The remainder came from grants and other sources, the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.